Persistence of transplacental antibodies, acquired from maternal COVID-19 vaccination or SARs-CoV-2 infection during pregnancy, in infants age less than 6 months old. COVID-19 vaccine, anti-SARs-CoV-2 antibodies, antibody, pregnant women, neonate
Conditions
Interventions
Healthy neonates or infants, aged 0 days to 4 months old, (gestational age more than 32 weeks at birth) born to mothers aged 18 to 45 years old who received at least 1 dose of any COVID-19 vaccine typ
Other
Healthy neonates
Sponsors
National Vaccine Institute
Eligibility
Sex/Gender
All
Age
No minimum to 4 Months
Inclusion criteria
Inclusion criteria: Healthy neonates or infants, aged 0 days to 4 months old, (gestational age more than 32 weeks at birth) born to mothers aged 18 to 45 years old who received at least 1 dose of any COVID-19 vaccine types (mRNA, viral-vector or inactivated vaccine) in any of the following period: - at least 1 dose or recent booster dose within 3 months before pregnancy - during pregnancy but not exceed 2 weeks before delivery
Exclusion criteria
Exclusion criteria: Neonates or infants who had any medical-related problems for example preterm (GA < 32 weeks at birth), congenital anomalies, severe birth infection or complications, immune deficiency and receiving any blood components products or immunomodulators as well as pregnant women with severe medical illnesses (e.g., exposure to immunosuppressive drugs, HIV infection, severe sepsis) that might affect antibody responses must be excluded from this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Persistence of antibodies after the end of recriutment geometric mean | — |
Secondary
| Measure | Time frame |
|---|---|
| breastfeeding after the end of recruitment breakthrogh COVID-19 infection | — |
Countries
Thailand
Contacts
Public ContactKeswadee Lapphra
Siriraj Hospital, Faculty of Medicine, Mahidol University
Outcome results
None listed